Free-text search
Articles per year:
Content Types
-
Novo Nordisk Pharmatech CEO to step down
Ulla Grove Krogsgaard Thomsen has decided to leave Novo Nordisk Pharmatech to pursue af different career.
-
Novartis hit by another major setback – shares plunge
Novartis has suffered another major pipeline setback. A key drug candidate acquired through its $12bn takeover of Avidity has failed in phase III, sending the company’s shares down around 10 per cent.
-
BII injects fresh millions into six ‘promising’ Danish startups
BioInnovation Institute (BII) is allocating new convertible loans of EUR 1.3 million to six Danish startups previously backed by the organisation.
-
Political consensus on how to bring more new medicines to Sweden
Sweden is losing ground when it comes to access to new medicines. Ahead of the election, the country’s parliamentary parties are unusually united on what needs to change. Now, pharmaceutical industry association Lif is calling for that consensus to be turned into action.
-
Novo Nordisk halts two more heart drug trials
Novo Nordisk is discontinuing two Phase III trials of its drug candidate ziltivekimab in heart failure and inflammation.
-
Four in ten children shed obesity in Novo trial
A phase III study testing semaglutide in children with obesity met its primary endpoint, Novo Nordisk reports.
-
“Not the results we hoped for” – Novartis’ heart study shows no benefit
Novartis’ drug candidate pelacarsen, aimed at a well‑known cardiovascular risk factor, failed to reduce the risk of heart attack, stroke and cardiovascular death in a large Phase III trial.
-
FDA Breakthrough Device Designation lifts Neola shares
Lund-based Neola Medical has been granted the FDA’s Breakthrough Device Designation for Neola, the company’s medical device for continuous lung monitoring in preterm born babies.
-
Astra Zeneca receives US approval for Etcamah
The pharmaceutical company Astra Zeneca has received accelerated FDA approval for Etcamah in combination with a CDK4/6 inhibitor for advanced HR-positive, HER2-negative breast cancer with an ESR1 mutation.
-
Dialysis company hit with $15M bill after massive patient data breach
A cyberattack last year exposed the personal data of millions of patients at dialysis provider DaVita. Now the bill has arrived for the company: 15 million dollars in damages.
-
Sweden takes new steps to tackle oestrogen shortages
Sweden has struggled with shortages of oestrogen medicines for years, forcing women going through the menopause to switch products or search from pharmacy to pharmacy. Now, new measures aim to make it easier for healthcare professionals to find alternatives – including medicines not marketed in Sweden.
-
Lithuania accelerates life science ambitions with major cell therapy investment
A new center for cell therapy and personalized medicines has opened in the Lithuanian capital, Vilnius.
-
BII and GU Ventures collaborate on oligonucleotide project
Denmark’s BioInnovation Institute (BII) and Sweden’s GU Ventures are collaborating through a new cross-border project focused on therapeutic oligonucleotides.
-
AbbVie’s myeloma candidate hits both goals in Phase III
The pharmaceutical company Abbvie's etentamig met both primary endpoints in the Phase III CERVINO study in relapsed or refractory multiple myeloma.
-
She will lead Unilabs in the Nordics
Unilabs has appointed Ellen Gijsbers as General Manager Nordics.
-
IRLAB CEO to step down
Kristina Torfgård will step down as CEO of Swedish pharmaceutical company IRLAB Therapeutics in the first quarter of 2027, the company announced.
-
Novartis reshapes biologics business – 130 jobs at risk
Novartis is continuing to reshape its European operations. Around 130 jobs could now be cut in Basel as the pharmaceutical giant consolidates its biologics development activities and relocates parts of its manufacturing operations.
-
Chinese approval for Leqembi auto-injector
BioArctic’s partner Eisai has received approval in China for the subcutaneous auto-injector formulation of Leqembi as an initial treatment for early Alzheimer’s disease, according to a press release.
-
A turning point for personalized cancer vaccines – ”The field is moving quickly now”
The progress of a new personalised drug candidate for skin cancer is raising great hopes in the research community. ”It strengthens confidence in the entire class of neoantigen‑based vaccines”, says Sara Mangsbo, professor of cancer immunotherapy at Uppsala University.
-
Swedish‑developed CT scanner cleared in Europe: “Very exciting”
GE Healthcare’s photon‑counting computed tomography (PCCT) system, Photonova Spectra, has now received CE Mark, enabling the Swedish‑developed technology to be sold across the European market.
-
The newborn injection more parents are choosing to decline
A vitamin K injection has long been routine for newborn babies, protecting them against rare but potentially serious bleeding. But in the US, a growing number of parents are choosing to decline the injection – a trend also seen in Sweden.
-
BTK inhibitor shows efficacy in MS – without liver toxicity
A new MS treatment from Novartis has met its targets in two Phase III studies – without showing the liver-related side effects that have previously characterized the drug class.
-
Norwegian drug developer expands into other Scandinavian markets
After four years, NordicRWE has turned to Sweden and Denmark to broaden its business
-
Orexo CEO on settlement: “Very mixed feelings”
After more than $14m in legal fees and years of uncertainty, Orexo is closing in on a settlement with the US Department of Justice.
BREAKING